Comparisons of clinical characteristics, prognosis, epidemiological factors, and genetic susceptibility between HER2 ‐low and HER2 ‐zero breast cancer among Chinese females
Cancer Medicine · 2023
DOI: 10.1002/cam4.6129 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Lu Zheng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, Tianjin's Key Laboratory of Molecular Cancer Epidemiology, National Clinical Research Center for Cancer…. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Genetic Predisposition to Disease. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese National Key Research and Development Project, National Natural Science Foundation of China, Tianjin Health Committee Foundation.
Abstract (Originalsprache)
Background
Traditional human epidermal growth factor receptor 2 (HER2)‐negative breast cancer (BC) is recommended to be divided into HER2‐low and HER2‐zero subtypes due to different prognosis. However, few studies investigated their differences in clinical characteristics and prognosis among Chinese HER2‐negative BC and their stratified differences by hormone receptor (HR), while fewer studies investigated their differences in epidemiological factors and genetic susceptibility.
Methods
A total of 11,911 HER2‐negative BC were included to compare the clinical characteristics and prognosis between HER2‐zero and HER2‐low BC, and 4227 of the 11,911 HER2‐negative BC were further compared to 5653 controls to investigate subtype‐specific epidemiological factors and single nucleotide polymorphisms(SNPs).
Results
Overall, 64.2% of HER2‐negative BC were HER2‐low BC, and the stratified proportions of HER2‐low BC were 61.9% and 75.2% for HR‐positive and HR‐negative BC, respectively. Compared to HER2‐zero BC, HER2‐low BC among HR‐positive BC showed younger age at diagnosis, later stage, poorer differentiation, and higher Ki‐67, while elder age at diagnosis and lower mortality were observed for HER2‐low BC among HR‐negative BC (all p values
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, Tianjin's Key Laboratory of Molecular Cancer Epidemiology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Me…
- Department of Infectious Disease Control and Prevention, Heping Centers for Disease Control and Prevention of Tianjin, Tianjin, China.
- Department of Breast Cancer, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
ORCID-Profile: Fengju Song
Förderung
- Chinese National Key Research and Development Project
- National Natural Science Foundation of China
- Tianjin Health Committee Foundation
- Tianjin Science and Technology Committee Foundation
Zitieren
APA
Zheng, L., Zhang, Y., Wang, Z., Wang, H., Hao, C., Li, C., Zhao, Y., Lyu, Z., Song, F., Chen, K., Huang, Y., & Song, F. (2023). Comparisons of clinical characteristics, prognosis, epidemiological factors, and genetic susceptibility between HER2 ‐low and HER2 ‐zero breast cancer among Chinese females. Cancer Medicine. https://doi.org/10.1002/cam4.6129
Vancouver
Zheng L, Zhang Y, Wang Z, Wang H, Hao C, Li C, et al. Comparisons of clinical characteristics, prognosis, epidemiological factors, and genetic susceptibility between HER2 ‐low and HER2 ‐zero breast cancer among Chinese females. Cancer Medicine. 2023. doi:10.1002/cam4.6129
BibTeX
@article{Zheng2023,
author = {Zheng, Lu and Zhang, Yunmeng and Wang, Zhipeng and Wang, Huan and Hao, Chunfang and Li, Chenyang and Zhao, Yanrui and Lyu, Zhangyan and Song, Fangfang and Chen, Kexin and Huang, Yubei and Song, Fengju},
title = {Comparisons of clinical characteristics, prognosis, epidemiological factors, and genetic susceptibility between HER2 ‐low and HER2 ‐zero breast cancer among Chinese females},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6129}
}
EUVIMED